Asset Details
Do you wish to reserve the book?
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion
Do you wish to request the book?
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion
2024
Overview
As a strategy to improve the therapeutic success of chimeric antigen receptor T cells (CART) directed against solid tumors, we here test the combinatorial use of CART and IMSA101, a newly developed stimulator of interferon genes (STING) agonist. In two syngeneic tumor models, improved overall survival is observed when mice are treated with intratumorally administered IMSA101 in addition to intravenous CART infusion. Transcriptomic analyses of CART isolated from tumors show elevated T cell activation, as well as upregulated cytokine pathway signatures, in particular IL-18, in the combination treatment group. Also, higher levels of IL-18 in serum and tumor are detected with IMSA101 treatment. Consistent with this, the use of IL-18 receptor negative CART impair anti-tumor responses in mice receiving combination treatment. In summary, we find that IMSA101 enhances CART function which is facilitated through STING agonist-induced IL-18 secretion.
It has been previously suggested that STING agonists can improve response to CAR-T therapy. Here the authors report the characterization of the STING agonist IMSA101, showing that STING-induced IL18 secretion enhances CAR-T activity in preclinical cancer models.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Agonists
/ Animals
/ Antigens
/ Female
/ Humanities and Social Sciences
/ Humans
/ Immunotherapy, Adoptive - methods
/ Lymphocyte Activation - drug effects
/ Membrane Proteins - agonists
/ Membrane Proteins - genetics
/ Membrane Proteins - metabolism
/ Mice
/ Receptors, Chimeric Antigen - immunology
/ Receptors, Chimeric Antigen - metabolism
/ Science
/ T-Lymphocytes - drug effects
/ Tumors
